The Association of Clinical Oncology congratulates the eleven practices that prioritized the quality of care they provide by achieving the Quality Oncology Practice Initiative (QOPI®) Certification in the second half of 2020.
ALEXANDRIA, Va. – Eight oncology practices in eight different U.S. metropolitan areas with high rates of breast cancer disparities between Black and white Americans have been selected to participate in the American Society of Clinical Oncology’s (ASCO) quality programs, including the Quality Oncology Practice Initiative (QOPI®) and Quality Training Program (QTP). Today ASCO and Susan G. Komen (Komen), with funding from the Fund II Foundation for each practice’s training and participation, announced the recipients. The three-year program, will be administered through Conquer Cancer, the ASCO Foundation.
On the eve of his inauguration, the Association for Clinical Oncology (ASCO) congratulates Joseph R. Biden, Jr., the 46th President of the United States.
The Association for Clinical Oncology (ASCO) applauds the decision by the U.S. District Court for the District of Maryland to grant a temporary restraining order on the implementation of the Most Favored Nation (MFN) Interim Final Rule. Judge Blake’s decision delays the model’s implementation for 14 days while she considers a preliminary injunction, which would further delay the model. The decision notes that there is likely to be irreparable harm if the rule goes into effect January 1, suggesting that the preliminary injunction will likely be granted.
Congress took a giant step forward to reduce health disparities by expanding clinical trial access to more than 41.6 million Medicaid beneficiaries through passage of the bipartisan CLINICAL TREATMENT Act as part of its end-of-year legislative package. We commend Congress for passing this commonsense fix to increase the diversity of participants in clinical trials, improve the validity of clinical research, and help reduce disparities in treatment outcomes for people with life-threatening diseases—disparities that have only been magnified by the COVID-19 pandemic.
The American Society of Clinical Oncology (the Society), an affiliated organization of the Association for Clinical Oncology (the Association), collectively known as ASCO, submitted an amicus curiae brief in support of motions in four cases to enjoin the Most Favored Nation (MFN) Model from taking effect on January 1, 2021. The Society’s friend-of-the-court brief urges the courts to stop implementation of the model, citing its devastating impact on patients.
The Association for Clinical Oncology (ASCO) opposes the Most Favored Nation (MFN) Model for Medicare Part B drug reimbursement, which outlines a structured, nationwide, mandatory demonstration that will be phased in over four years, with full implementation for the final three years of the seven-year model. This plan effectively overrides a statutory provision under the guise of a demonstration project by imposing a new reimbursement model on cancer care absent any evidence that it can lower costs without negative consequences for Medicare beneficiaries.
ASCO applauds Senators Richard Burr (R-NC) and Ben Cardin (D-MD) for introducing bipartisan legislation to expand access to clinical trials and improve the quality of cancer research. The CLINICAL TREATMENT Act (S. 4742) would require Medicaid to guarantee coverage of the routine care costs of clinical trial participation for Medicaid enrollees with a life-threatening condition.
The Association for Clinical Oncology (ASCO) presented its Advocate of the Year Award to Carolyn Hendricks, MD, FASCO, for her exceptional contributions and commitment to the Association’s advocacy efforts.
The Association for Clinical Oncology (ASCO) today presented Representative Rosa DeLauro (CT-3) with the annual Congressional Champion for Cancer Care Award in recognition of her exceptional commitment to bipartisan support for cancer research and treatment. The award honors a Member of Congress who is a leading champion for patients and survivors of cancer, their families, and their cancer care teams.
The Association for Clinical Oncology (ASCO) today released a statement regarding concerns that the U.S. Department of Health and Human Services (HHS) rescission of all guidance and informal issuances related to the Food and Drug Administration’s (FDA) current oversight of the premarket review and approval process for laboratory developed tests (LDTs) puts the safety of cancer treatments at risk.
The Association for Clinical Oncology (ASCO) today released a statement applauding the implementation of the Research to Accelerate Cures and Equity (RACE) for Children Act. As of today, applications to the Food and Drug Administration for marketing approval of new drugs and biological products—including orphan drugs that have relevance to pediatric cancer—must include an assessment of pediatric use.
The Association of Clinical Oncology congratulates the eighteen practices that prioritized the quality of care they provide by achieving the Quality Oncology Practice Initiative (QOPI®) Certification in the second quarter of 2020.
ALEXANDRIA, Va. -- Twenty-seven practices elevated their standard of care and achieved Quality Oncology Practice Initiative (QOPI®) Certification in the first quarter of this year. The Association for Clinical Oncology (Association) commends these practices that have demonstrated their commitment to providing the highest-quality oncology care to their patients, communities, and contemporaries.
ASCO today announced the results of a survey that tracked the initial impact of the COVID-19 pandemic on cancer clinical trials, highlighted a new research initiative to address the data gap on the coronavirus’ effect on individuals with cancer, and set forth a road to recovery as the cancer care delivery system prepares for life after COVID-19.